Subject(s)
Coloring Agents/adverse effects , Dermatitis, Contact/etiology , Nails , Naphthoquinones/adverse effects , Adult , Female , HumansABSTRACT
A case of contact urticaria associated with a serous rhinitis, dyspnea, wheezing, and a dry cough appearing after the application of a hair conditioner on the scalp is reported. Prick test results with the conditioner diluted at 1/16 and 1/8 were strongly positive (+3), as well as a prick test (+3) with one component of the conditioner called "hydrolyzed proteins," which contained hydrolyzed bovine collagen and stearyl trimethylammonium chloride.
Subject(s)
Hair Preparations/adverse effects , Hypersensitivity, Immediate/etiology , Urticaria/etiology , Adult , Animals , Cattle , Collagen/adverse effects , Female , Humans , Hypersensitivity, Immediate/physiopathology , Patch TestsSubject(s)
Benzoquinones/adverse effects , Dermatitis, Allergic Contact/etiology , Wood , Female , Humans , India , Middle AgedABSTRACT
BACKGROUND: Contact hypersensitivity to corticosteroids is increasingly reported and has been identified as a problem of considerable clinical relevance. The prevalence of positive patch tests to corticosteroids ranges from 0.2 up to 5%. OBJECTIVE: The prevalence of positive patch tests to corticosteroids in Switzerland was determined in a multi-centre study of patients undergoing routine patch tests. METHODS: As representatives of corticosteroid groups, the following substances were used for screening: tixocortol pivalate and hydrocortisone for group A (hydrocortisone type), hydrocortisone butyrate for group D (hydrocortisone butyrate type) and budesonide for both groups B (triamcinolone type) and D. Patients positive for at least one corticosteroid were retested with the screening series and 12 corticosteroids commonly used in Switzerland. RESULTS: Among 3,016 consecutive patients, 65 individuals (2.2%) with a total of 106 positive reactions were found. Retesting showed a concordance of 70-98%, depending on the corticosteroid and the score of the positive reaction. In the subsequently tested corticosteroid series including 12 substances, 19 out of 56 screening-positive patients had a positive result to one or several corticosteroids. There were only few evident cross-reactive patterns in between the corticosteroids tested. CONCLUSIONS: Corticosteroids should be included in routine patch testing, because contact sensitization to a corticosteroid is of considerable practical importance. We confirm that as markers of corticosteroid sensitization tixocortol pivalate, budesonide and hydrocortisone butyrate may be suited, because there is no single corticosteroid which is a marker for all four corticosteroid groups. Patch test reactions of 2+ or higher have a better reproducibility than 1+ reactions.
Subject(s)
Adrenal Cortex Hormones/adverse effects , Dermatitis, Contact/etiology , Drug Eruptions/etiology , Administration, Topical , Adolescent , Adrenal Cortex Hormones/immunology , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents/adverse effects , Budesonide , Child , Cross Reactions , Dermatitis, Contact/epidemiology , Dermatitis, Contact/immunology , Drug Eruptions/epidemiology , Drug Eruptions/immunology , Female , Humans , Hydrocortisone/adverse effects , Male , Middle Aged , Patch Tests , Pregnenediones/adverse effects , Prevalence , Switzerland/epidemiologySubject(s)
Acetylcysteine/therapeutic use , Antioxidants/therapeutic use , Dermatitis, Irritant/prevention & control , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Acetylcysteine/administration & dosage , Acetylcysteine/pharmacology , Antioxidants/administration & dosage , Antioxidants/pharmacology , Dermatitis, Irritant/physiopathology , Dimethyl Sulfoxide/adverse effects , Edema/chemically induced , Edema/physiopathology , Edema/prevention & control , Erythema/chemically induced , Erythema/physiopathology , Erythema/prevention & control , Humans , Ointments , Sodium Dodecyl Sulfate/adverse effects , Tumor Necrosis Factor-alpha/physiologyABSTRACT
Emulsifiers are common constituents of most topical preparations. To study the sensitization rate in a population with frequent use of these agents, we selected 47 patients with chronic or recurrent (> 1 year) inflammatory skin disease (leg ulcers, contact dermatitis, atopic dermatitis, psoriasis) for patch testing with the following emulsifiers: Tween 40 (polyoxyethylene sorbitan monopalmitate). Tween 80 (polyoxyethylene sorbitan monooleate), Span 60 (sorbitan monostearate), Span 80 (sorbitan monooelate), Arlacel 83 (sorbitan sesquioleate), Atlas G 2162 (polyoxyethylene oxypropylene stearate), Atlas G 1441 (polyoxyethylene sorbitol lanolin derivative), triethanolamine, Lanette O (cetylstearyl alcohol), Lanette N. 12 patients had at least 1 positive reaction (25.5%) at 3 or 4 days. Among them, 10 had leg ulcers (43.4% of the leg ulcer group), and 2 had contact dermatitis (13.3% of the contact dermatitis group). No positive reaction was observed in the other patients. When the patients were tested with their own topical preparations or wound dressings, 6 of them, all with leg ulcers, had positive reactions. These results show a surprisingly high prevalence of sensitization to emulsifiers in patients with chronic leg ulcers, in contrast to patients with other inflammatory skin diseases.
Subject(s)
Dermatitis, Allergic Contact/etiology , Excipients/adverse effects , Leg Ulcer/complications , Skin Diseases/complications , Administration, Topical , Chronic Disease , Dermatitis/complications , Dermatitis/drug therapy , Dermatitis/immunology , Dermatitis, Allergic Contact/immunology , Excipients/administration & dosage , Humans , Leg Ulcer/drug therapy , Leg Ulcer/immunology , Patch Tests , Psoriasis/complications , Psoriasis/drug therapy , Psoriasis/immunology , Skin Diseases/drug therapy , Skin Diseases/immunologySubject(s)
Antifungal Agents/adverse effects , Dermatitis, Allergic Contact/diagnosis , Drug Eruptions/diagnosis , Hand Dermatoses/diagnosis , Imidazoles/adverse effects , Tinea Pedis/diagnosis , Antifungal Agents/therapeutic use , Dermatitis, Allergic Contact/etiology , Diagnosis, Differential , Drug Eruptions/etiology , Hand Dermatoses/chemically induced , Humans , Imidazoles/therapeutic use , Male , Middle Aged , Syndrome , Tinea Pedis/chemically inducedABSTRACT
In an attempt to stop the evolution of recent-onset severe alopecia areata (AA), we tested pulse corticotherapy on 9 patients. Acceptance into the study was based on the following criteria: recent-onset AA (< 1 year), AA in an active state, bald surface > 30% of the scalp, no contraindication to pulse corticotherapy. Each patient was given 250 mg i.v. of methylprednisolone twice a day on 3 successive days. In 8 patients the course of the ongoing episode of AA was stopped. At the 6-month follow-up, a regrowth on 80-100% of the bald surface was observed in 6 patients. One patient did not respond to treatment, and 2 had less than 50% of regrowth. This open study suggests that pulse corticotherapy: (1) can stop the course of severe AA in an active state, (2) is well tolerated without major side effects and (3) does not permit a stable control of AA of more than 1 year duration. This treatment seems to be indicated for severe AA of recent onset.
Subject(s)
Alopecia Areata/drug therapy , Methylprednisolone/therapeutic use , Adolescent , Adult , Alopecia Areata/pathology , Alopecia Areata/prevention & control , Drug Administration Schedule , Drug Tolerance , Face , Female , Follow-Up Studies , Hair/growth & development , Hair/pathology , Humans , Infusion Pumps , Infusions, Intravenous , Male , Methylprednisolone/administration & dosage , Middle Aged , Scalp/pathologyABSTRACT
The angry back or excited skin syndrome consists of patch test reactions that are positive only when associated with adjacent or distant inflammatory skin lesions. Recent experiments in the mouse and man have provided the knowledge on the critical role of tumor necrosis factor in contact dermatitis as well as its importance for the induction of adhesion molecules. Based on these new findings we speculate on mechanisms that might explain this poorly understood clinical phenomenon.